The calculation of probabilities in rejecting bioequivalence

Area of Science:

• Pharmacokinetics and Biopharmaceutics
• Statistical Methods in Clinical Trials
• Drug Formulation Analysis

Background:

• Bioequivalence studies are crucial for generic drug approval.
• Accurate probability calculations are essential for robust study design and interpretation.
• Existing methods may lack precision or applicability across diverse trial designs.

Purpose of the Study:

• To develop methods for deriving precise lower and upper bounds for the probability of rejecting bioequivalence.
• To provide exact probabilities for bioequivalence assessments, particularly when formulations are not nearly identical.
• To establish a unified approach applicable to various clinical trial designs, including crossover and parallel groups.

Main Methods:

• Derivation of analytical methods to establish probability bounds for bioequivalence rejection.
• Application of these methods to two-way and higher-way crossover designs.
• Extension of methods to parallel groups designs.
• Formulation of equations for sample size determination based on derived probabilities.

Main Results:

• The derived lower and upper bounds converge to an exact probability, except when formulations are nearly identical.
• The methods provide accurate probabilities across different study designs (crossover, parallel groups).
• Sample size calculations can be directly derived from the established equations.
• Results show good agreement when compared with simulation-based probabilities.

Conclusions:

• The developed methods offer a precise and versatile approach for calculating bioequivalence rejection probabilities.
• These methods enhance the accuracy of statistical inference in bioequivalence studies.
• The ability to determine sample size directly simplifies study planning and resource allocation.
• The findings support more reliable decision-making in pharmaceutical development and regulatory submissions.